VolitionRX Ltd
VNRX
查看詳細走勢圖
0.246USD
-0.001-0.40%
收盤 02/06, 16:00（美東）報價延遲15分鐘
26.97M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-0.40%
5天
-13.68%
1月
-11.13%
6月
-63.17%
今年開始到現在
-3.76%
1年
-60.30%
查看詳細走勢圖
TradingKey VolitionRX Ltd股票評分
單位: USD 更新時間: 2026-02-06操作建議
VolitionRX Ltd當前公司基本面數據相對謹慎，最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理，在生物技術與醫療研究行業排名160/392位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為2.17。中期看，股價處於下降通道。近一個月，市場表現非常差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
VolitionRX Ltd評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
VolitionRX Ltd亮點
亮點風險
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
業績高增長
公司營業收入穩步增長，連續3年增長302.59%
業績增長期
公司處於發展階段，最新年度總收入1.23M美元
估值高估
公司最新PE估值-1.08，處於3年歷史高位
機構加倉
最新機構持股26.12M股，環比增加7.04%
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉，最新持倉78.00K股
分析師目標
基於
6
分析師
買入
評級
2.167
目標均價
+777.19%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
VolitionRX Ltd新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
VolitionRX Ltd簡介
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
公司代碼VNRX
公司VolitionRX Ltd
CEOButera (Salvatore Thomas)
網址https://volition.com/
相關品種
+3.66%
+3.14%
+0.93%
+2.01%
+1.82%
+1.60%
-0.95%
+4.49%
+2.10%
+9.92%
+2.76%
+4.15%
+1.79%
+4.17%
+0.72%
+1.10%
+2.46%
0.00%
+0.51%
+0.54%熱門品種
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
70985.450
+1015.320 (+1.45%)
282.580
+22.390 (+8.61%)
2093.810
+42.080 (+2.05%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
